InvestSMART

Artrya Limited (ASX: AYA) - Announcements

Current share price for AYA : $5.820 0.14 (2.46%)+

ASX company news and announcements for Artrya Limited (AYA) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Artrya Limited (AYA) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Artrya Limited (AYA), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Artrya Limited (AYA)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$948 Notification of cessation of securities - AYA 9 Mar 2026 5:41PM $3.020 $5.820 risen by 92.72%
$948 Company Presentation 9 Mar 2026 9:40AM $3.400 $5.820 risen by 71.18%
$948 S&P DJI Announces March 2026 Quarterly Rebalance 6 Mar 2026 5:05PM $3.400 $5.820 risen by 71.18%
$948 Becoming a substantial holder 4 Mar 2026 5:00PM $3.020 $5.820 risen by 92.72%
$948 Appendix 4D and Interim Financial Report 25 Feb 2026 7:58PM $3.290 $5.820 risen by 76.90%
$948 Change in substantial holding 24 Feb 2026 5:26PM $3.070 $5.820 risen by 89.58%
$948 Notification of cessation of securities - AYA 20 Feb 2026 6:44PM $3.300 $5.820 risen by 76.36%
$948 Initial Director's Interest Notice 19 Feb 2026 9:20AM $3.230 $5.820 risen by 80.19%
$948 Appointment of Non-Executive Director 19 Feb 2026 9:10AM $3.230 $5.820 risen by 80.19%
$948 Change in substantial holding from WAX/WAA/WAM/WMI 2 Feb 2026 5:52PM $3.560 $5.820 risen by 63.48%
$948 Change in substantial holding 2 Feb 2026 5:30PM $3.560 $5.820 risen by 63.48%
$948 Ceasing to be a substantial holder 2 Feb 2026 5:04PM $3.560 $5.820 risen by 63.48%
$948 Dignity Health Arizona joins Sapphire Study 2 Feb 2026 8:40AM $3.530 $5.820 risen by 64.87%
$948 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2026 9:39AM $3.740 $5.820 risen by 55.61%
$948 HCA Midwest Health Joins Sapphire Study 29 Jan 2026 7:10PM $3.740 $5.820 risen by 55.61%
$948 Artrya Management Update 27 Jan 2026 9:35AM $4.220 $5.820 risen by 37.91%
$948 Becoming a substantial holder 29 Dec 2025 5:05PM $4.740 $5.820 risen by 22.78%
$948 Cone Health Becomes Third U.S. Customer 23 Dec 2025 9:35AM $3.860 $5.820 risen by 50.78%
$948 Ceasing to be a substantial holder 17 Dec 2025 5:02PM $3.870 $5.820 risen by 50.39%
$948 First Revenues from Salix Coronary Plaque Module 12 Dec 2025 9:33AM $3.870 $5.820 risen by 50.39%
$948 Second US Commercial Customer - Northeast Georgia 8 Dec 2025 9:23AM $3.450 $5.820 risen by 68.70%
$948 S&P DJI Announces December 2025 Quarterly Rebalance 5 Dec 2025 5:06PM $3.450 $5.820 risen by 68.70%
$948 2025 Bell Potter Healthcare Conference Presentation 20 Nov 2025 1:03PM $3.170 $5.820 risen by 83.60%
$948 2025 Canaccord Healthcare Conference Presentation 20 Nov 2025 9:41AM $2.900 $5.820 risen by 100.69%
$948 Results of Annual General Meeting 13 Nov 2025 3:29PM $3.760 $5.820 risen by 54.79%

26 - 50 of 501 results

Page 2 of 21

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.